



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 31/505, 31/40, 31/365, 31/22, 31/44, 31/415, A61P 43/00	A1	(11) International Publication Number: WO 00/45818 (43) International Publication Date: 10 August 2000 (10.08.00)						
<p>(21) International Application Number: PCT/GB00/00280</p> <p>(22) International Filing Date: 1 February 2000 (01.02.00)</p> <p>(30) Priority Data:</p> <table border="0"> <tr> <td>9902591.8</td> <td>6 February 1999 (06.02.99)</td> <td>GB</td> </tr> <tr> <td>9902594.2</td> <td>6 February 1999 (06.02.99)</td> <td>GB</td> </tr> </table> <p>(71) Applicants (for all designated States except US): AS-TRAZENECA UK LIMITED [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB). THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN [GB/GB]; Regent Walk, Aberdeen AB24 3FX (GB).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): CAMERON, Norman, Eugene [GB/GB]; Institute of Medical Sciences, Diabetic Complications Laboratory, Foresterhill, Aberdeen AB25 2ZD (GB). COTTER, Mary, Anne [GB/GB]; Institute of Medical Sciences, Diabetic Complications Laboratory, Foresterhill, Aberdeen AB25 2ZD (GB).</p> <p>(74) Agent: BROWN, Andrew, Stephen; AstraZeneca UK Limited, Global Intellectual Property, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).</p>		9902591.8	6 February 1999 (06.02.99)	GB	9902594.2	6 February 1999 (06.02.99)	GB	<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published</p> <p><i>With international search report.</i></p> <p><i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
9902591.8	6 February 1999 (06.02.99)	GB						
9902594.2	6 February 1999 (06.02.99)	GB						
<p>(54) Title: USE OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE INHIBITORS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF DIABETIC NEUROPATHY</p>								
<p>(57) Abstract</p> <p>The present invention relates to a new use of a statin drug in the improvement of diabetic neuropathy, specifically in improving nerve conduction velocity and nerve blood flow in patients suffering diabetes, in particular to pharmaceutical combinations of the statin drug and other agents known to improve diabetic neuropathy such as an aldose reductase inhibitor (ARI), an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II (AII) antagonist which combinations are useful in the prevention and treatment of the complications of diabetes.</p>								

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

- 1 -

USE OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE INHIBITORS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF DIABETIC NEUROPATHY

The present invention relates to a new use of a statin drug in the improvement of diabetic neuropathy, specifically in improving nerve conduction velocity and nerve blood flow in patients suffering diabetes, in particular to pharmaceutical combinations of the statin drug and other agents known to improve diabetic neuropathy such as an aldose reductase inhibitor (ARI), an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II (AII) antagonist which combinations are useful in the prevention and treatment of the complications of diabetes.

3-Hydroxy-3-methylglutaryl Coenzyme A (HMG Co A) reductase inhibitors effectively inhibit cholesterol synthesis in the liver through stimulation of the low density lipoprotein (LDL) receptors. These drugs are currently pre-eminent in the treatment of all hypercholesterolaemia, except the relatively rarely occurring homozygous familial hypercholesterolaemia. Therapy with HMG Co A-reductase inhibitors may result in regression of atherosclerotic vascular lesions and several HMG Co A-reductase inhibitors have proven to reduce mortality. Various HMG Co A-reductase inhibitors are marketed, and are collectively referred to as 'statins'.

We have discovered that statin drugs, in particular (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof (the AGENT), the calcium salt of which is shown in Fig. 1 below, and atorvastatin produce an improvement in the nerve conduction velocity (NCV) and nerve blood flow in an animal model of diabetic neuropathy. Therefore, statin drugs may be used to improve diabetic neuropathy, whether in type I or type II diabetes.

Therefore we present as a first feature of the invention a method for treating neuropathy in a patient suffering from diabetes comprising administering to the patient a statin drug.

- 2 -

As a preferred feature of the invention we present a method for improving nerve conduction velocity and /or nerve blood flow in a patient suffering diabetic neuropathy comprising administering to the patient a statin drug.

- 5 Further features of the invention include use of a statin drug in the preparation of a medicament for use in the treatment of any of the conditions mentioned above.

Examples of statin drugs include, for example, pravastatin (PRAVACHOL™), lovastatin (MEVACOR™), simvastatin (ZOCOR™), cerivastatin (LIPOBAY™), fluvastatin
10 (LESCOL™), atorvastatin (LIPITOR™) and the AGENT, the structures of which are shown in Figure 1. Preferably the statin drug is atorvastatin or the AGENT. Preferably the AGENT is used at a dose of 5 to 80 mg per day.

The AGENT is disclosed in European Patent Application, Publication No. 0521471, and in
15 Bioorganic and Medicinal Chemistry, (1997), 5(2), 437-444 as an inhibitor of 3-hydroxy-3-methylglutaryl CoA reductase (HMG-CoA reductase). Preferably the calcium salt is used as illustrated in Figure 1.

Atorvastatin is disclosed in US 5,273,995; lovastatin is disclosed in US 4,231,938;
20 simvastatin is disclosed US 4,450,171 and US 4,346,227; pravastatin is disclosed in US 4,346,227; fluvastatin is disclosed in US 4,739,073; cerivastatin is disclosed in US 5,177,080 and US 5,006,530.

Other compounds which have inhibitory activity against HMG-CoA reductase can be readily
25 identified by using assays well known in the art. Examples of such assays are disclosed in US 4,231,938 at column 6 and WO84/02131 at pages 30-33.

It will be appreciated that the statin drug may be administered in accordance with the invention in combination with other drugs used for treating diabetes or the complications of
30 diabetes, such as neuropathy, nephropathy, retinopathy and cataracts. Examples of such treatments include insulin sensitising agents, insulin and oral hypoglycaemics (these are

- 3 -

divided into four classes of drug - sulfonylureas, biguanides, prandial glucose regulators and alpha-glucosidase inhibitors). Examples of insulin sensitising agents include, for example, troglitazone, rosiglitazone, pioglitazone, MCC-555, (S)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl]propanoic acid and 3-{4-[2-(4-*tert*-

5, butoxycarbonylamino)phenyl]ethoxy}phenyl}-(S)-2-ethoxy propanoic acid. Examples of sulfonylureas are glimepiride, glibenclamide, gliclazide, glipizide, gliquidone and tolazamide. An example of a biguanide is metformin. An example of an alpha-glucosidase inhibitor is acarbose. An example of a prandial glucose regulator is repaglinide.

10 Other treatments are known also to improve NCV in diabetic neuropathy and as such these represent preferred combinations of the invention. Examples of such treatments include aldose reductase inhibitors, ACE inhibitors and AII antagonists.

The use of aldose reductase inhibitors or ACE inhibitors in improving NCV and treating
15 diabetic neuropathy is disclosed in PCT/GB98/01959. The use of AII antagonists in improving NCV and treating diabetic neuropathy is disclosed in WO93/20816.

Suitable aldose reductase inhibitors include, for example, epalrestat, tolrestat, ponolrestat, zopolrestat, AD-5467, SNK-860, ADN-138, AS-3201, zenarestat, sorbinil, methosorbinil,
20 imirestat and minalrestat (WAY-121509).

Suitable ACE inhibitors include, for example, benazepril, benazeprilat, captopril, delapril, fentiapril, fosinopril, imidopril, libenzapril, moexipril, pentopril, perindopril, pivopril, quinapril, quinaprilat, ramipril, spirapril, spiraprilat, trandolapril, zofenopril, ceronapril,
25 enalapril, indolapril, lisinopril, alacepril, and cilazapril. A preferred ACE inhibitor includes, for example, lisinopril, or a pharmaceutically acceptable salt thereof.

Suitable AII antagonists include, for example, losartan, irbesartan, valsartan and candesartan. A preferred AII antagonist is candesartan.

- 4 -

Independent aspects of the present invention include a pharmaceutical combination comprising any one of the statin drugs identified above, preferably the AGENT or atorvastatin, and any one of the named ACE inhibitors identified above, or anyone of the aldose reductase inhibitors identified above, or any one of the AII antagonists identified
5 above. Accordingly, further independent aspects of the present invention include the following:

- (1) A pharmaceutical combination comprising the AGENT and lisinopril;
- 10 (2) A pharmaceutical combination comprising atorvastatin and lisinopril;
- (3) A pharmaceutical combination comprising fluvastatin and lisinopril;
- (4) A pharmaceutical combination comprising pravastatin and lisinopril;
- 15 (5) A pharmaceutical combination comprising cerivastatin and lisinopril;
- (6) A pharmaceutical combination comprising the AGENT and candesartan;
- 20 (7) A pharmaceutical combination comprising the AGENT, or atorvastatin, and (S)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl]propanoic acid or 3-{4-[2-(4-*tert*-butoxycarbonylaminophenyl)ethoxy]phenyl}-(S)-2-ethoxy propanoic acid

The 'pharmaceutical combination' may be achieved by dosing each component drug of the
25 combination to the patient separately in individual dosage forms administered together or sequentially. Alternatively the 'pharmaceutical combination' may be together in the same unit dosage form.

Therefore, as a further aspect of the invention we represent a pharmaceutical composition
30 comprising a pharmaceutical combination as described herein above together with a pharmaceutically acceptable carrier and/or diluent.

- 5 -

Independent aspects of the present invention include a pharmaceutical composition comprising any one of the statin drugs identified above, preferably the AGENT or atorvastatin, and any one of the named ACE inhibitors identified above, or any one of the
5 aldose reductase inhibitors identified above, or any one of the AII antagonists identified above together with a pharmaceutically acceptable carrier and/or diluent. Accordingly, further independent aspects of the present invention include the following:

- 10 (1) A pharmaceutical composition comprising the AGENT and lisinopril;
- (2) A pharmaceutical composition comprising atorvastatin and lisinopril;
- (3) A pharmaceutical composition comprising fluvastatin and lisinopril;
- 15 (4) A pharmaceutical composition comprising pravastatin and lisinopril;
- (5) A pharmaceutical composition comprising cerivastatin and lisinopril;
- (6) A pharmaceutical composition comprising AGENT and candesartan; and
- 20 (7) A pharmaceutical composition comprising the AGENT, or atorvastatin, and (S)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl]propanoic acid or 3-{4-[2-(4-*tert*-butoxycarbonylaminophenyl)ethoxy]phenyl}-(S)-2-ethoxy propanoic acid; and
- 25 together with a pharmaceutically acceptable carrier and/or diluent.

A preferred pharmaceutical composition of the invention comprises the AGENT or atorvastatin and an ACE inhibitor (including any one of the ACE inhibitors specifically named above, in particular lisinopril), together with a pharmaceutically acceptable carrier
30 and/or diluent.

A preferred pharmaceutical composition of the invention comprises the AGENT or atorvastatin and an aldose reductase inhibitor (including any one specifically named above), together with a pharmaceutically acceptable carrier and/or diluent.

- 5 A preferred pharmaceutical composition of the invention comprises the AGENT or atorvastatin and an AII antagonist (including any one specifically named above and preferably candesartan), together with a pharmaceutically acceptable carrier and/or diluent.

The pharmaceutical compositions of the present invention may be administered in a standard
10 manner for example by oral or parenteral administration, using conventional systemic dosage forms, such as a tablets, capsules, pills, powders, aqueous or oily solutions or suspensions, emulsions, sterile injectable aqueous or oily solutions or suspensions. These dosage forms will include the necessary carrier material, excipient, lubricant, buffer, bulking agent, anti-oxidant, dispersant or the like. In particular, compositions for oral administration are
15 preferred.

The dose of a statin drug, an aldose reductase inhibitor, an AII antagonist or an ACE inhibitor which can be administered in accordance with the present invention depends on several factors, for example the age, weight and the severity of the condition under treatment, as well
20 as the route of administration, dosage form and regimen and the desired result, and additionally the potency of the statin drug, aldose reductase inhibitor, AII antagonist and ACE inhibitor employed in the composition. In addition, account should be taken of the recommended maximum daily dosages for the ACE inhibitors.

25 Prolonged administration of an ACE inhibitor at a therapeutically effective dose may be deleterious or give rise to side effects in certain patients, for example it may lead to significant deterioration of renal function, induce hyperkalemia, neutropenia, angioneurotic oedema, rash or diarrhoea or give rise to a dry cough. Administration of an ARI may also give rise to deleterious effects or side effects at the dose required to inhibit the enzyme aldose reductase
30 sufficiently to produce a significant beneficial therapeutic effect. The present invention lessens the problems associated with administration of an ARI or an ACE inhibitor alone

- 7 -

and/or provides a means for obtaining a therapeutic effect which is significantly greater than that otherwise obtainable with the single agents when administered alone. Furthermore, diabetic neuropathy involve a complex mechanism or number of mechanisms, which initiate a cascade of biochemical alterations that in turn lead to structural changes. These may result in a diverse patient population. The present invention therefore provides the additional advantage that it allows tailoring of treatment to the needs of a particular patient population.

The combination of a statin, preferably atorvastatin or the AGENT, with and ACE inhibitor, preferably lisinopril, is either additive or synergistic in effect in the treatment of neuropathy, in particular NCV or nerve blood flow, in diabetic patients.

The combination of a statin, preferably atorvastatin or the AGENT, with and AII antagonist, preferably candesartan, is either additive or synergistic in effect in the treatment of neuropathy, in particular NCV or nerve blood flow, in diabetic patients.

A unit dosage formulation such as a tablet or capsule will usually contain, for example, from 1 mg to 100 mg of the statin drug, or/and from 0.1 mg to 500 mg of an aldose reductase inhibitor, or/and from 0.1 mg to 500 mg of an ACE inhibitor. Preferably a unit dose formulation will contain 5 to 80 mg of the statin drug, or/and 0.1 to 100 mg of an aldose reductase inhibitor, or/and 0.1 mg to 100 mg of an AII antagonist or/and 0.1 to 100 mg of an ACE inhibitor.

The present invention covers the pharmaceutical combination of (or product containing) the statin and an aldose reductase inhibitor, an AII antagonist or an ACE inhibitor for simultaneous, separate or sequential use in the treatment of diabetic neuropathy. In one aspect of the present invention, the AGENT drug and the aldose reductase inhibitor or AII antagonist or ACE inhibitor is presented in admixture in one pharmaceutical dosage form. In another aspect, the present invention covers the administration of separate unit dosages of the AGENT and aldose reductase inhibitor or AII antagonist or ACE inhibitor in order to achieve the desired therapeutic effect. Such separate unit dosages may be administered concurrently or sequentially as determined by the clinician. The present invention also covers an agent for

the treatment of diabetic neuropathy comprising a pharmaceutically acceptable carrier and/or diluent and, as active agents, a statin drug, preferably the AGENT or atorvastatin, and an aldose reductase inhibitor or an AII antagonist or an ACE inhibitor in quantities producing a synergistic therapeutic effect.

5

In another aspect of the invention there is provided a combination of pharmaceutical compositions for combination therapy of diabetic neuropathy, the combination consisting of a pharmaceutical composition comprising the statin drug and a pharmaceutical composition comprising an aldose reductase inhibitor or a pharmaceutical composition comprising an AII antagonist or a pharmaceutical composition comprising an ACE inhibitor.

10

A further aspect of the present invention comprises the use of a statin drug and an aldose reductase inhibitor or an AII antagonist or an ACE inhibitor in the preparation of a pharmaceutical composition for use in the treatment of diabetic neuropathy.

15

A further aspect of the present invention is a method for treating diabetic neuropathy wherein a therapeutically effective amount of a statin drug in combination with an aldose reductase inhibitor or an AII antagonist or an ACE inhibitor is administered systemically, such as orally or parenterally. Where the patient to be treated is normotensive, the ACE inhibitor or AII antagonist will preferably be administered in amounts below that required to cause a reduction in blood pressure. Where the patient to be treated is hypertensive, the ACE inhibitor or AII antagonist will preferably be used in amounts usually employed to treat hypertension.

20

The effect of a pharmaceutical composition of the present invention may be examined by using one or more of the published models of diabetic neuropathy well known in the art. The pharmaceutical compositions of the present invention are particularly useful for the prevention of, reducing the development of, or reversal of, deficits in nerve function found in diabetic patients, and therefore particularly useful in the treatment of diabetic neuropathy. This may be demonstrated, for example, by measuring markers such as nerve conduction velocity, nerve blood flow, nerve evoked potential amplitude, quantitative sensory testing, autonomic function testing and morphometric changes. Experimentally, studies analogous to those

25

30

described in Diabetologia, 1992, Vol. 35, pages 12-18 and 1994, Vol. 37, pages 651-663 may be carried out.

- A further aspect of the present invention is a method of treating or preventing the development of disease conditions associated with impaired neuronal conduction velocity in a warm-blooded animal (including a human being) requiring such treatment comprising administering to said animal a therapeutically effective amount of a pharmaceutical combination or composition as described above.
- 10 A further aspect of the present invention is a method of reversing impaired neuronal conduction velocity in a warm-blooded animal (including a human being) requiring such treatment comprising administering to said animal a therapeutically effective amount of a pharmaceutical combination or composition as described above.
- 15 Dosages of the AGENT may be administered according to the cholesterol lowering effect desired from a range of 5-80 mg per day in any number of unit dosages.

- Suitable dosages of the statins, ACE inhibitors, aldose reductase inhibitors or AII antagonists mentioned herein are those which are available commercially, and which may be further reduced as suggested herein, or as advised in such publications as Monthly Index of Medical Specialities (P.O.BOX 43, Ruislip, Middlesex, UK).
- 20

The following non-limiting Examples serve to illustrate the present invention.

25 **Example 1**

Suitable pharmaceutical compositions of an aldose reductase inhibitor (ARI) include the following:

- 10 -

Tablet 1

		<u>mg/tablet</u>
	ARI	100
	Lactose Ph. Eur.	182.75
5	Croscarmellose sodium	12.0
	Maize starch paste (5% w/v paste)	2.25
	Magnesium stearate	3.0

Tablet 2

10	ARI	50
	Lactose Ph.Eur.	223.75
	Croscarmellose sodium	6.0
	Maize starch	15.0
	Polyvinylpyrrolidone (5% w/v paste)	2.25
15	Magnesium stearate	3.0

Tablet 3

	ARI	1.0
	Lactose Ph. Eur.	93.25
20	Croscarmellose sodium	4.0
	Maize starch paste (5% w/v paste)	0.75
	Magnesium stearate	1.0

Capsule 1

25	ARI	10
	Lactose Ph. Eur.	488.5
	Magnesium stearate	1.5

- 11 -

Example 2

Suitable pharmaceutical compositions of an ACE inhibitor include the following:

Tablet 1

5	ACE Inhibitor	100
	Corn starch	50
	Gelatin	7.5
	Microcrystalline cellulose	25
	Magnesium stearate	2.5

10

Tablet 2

	ACE inhibitor	20
	Pregelatinised starch	82
	Microcrystalline cellulose	82
15	Magnesium stearate	1

Example 3

	Capsule	mg
20	The AGENT	5.0
	Lactose	42.5
	Corn starch	20.0
	Microcrystalline cellulose	32.0
	Pregelatinised starch	3.3
25	Hydrotalcite	1.1
	Magnesium stearate	1.1

Capsules containing 1, 2.5 or 10mg of the Agent may be obtained similarly using more or less lactose as appropriate., to achieve a fill weight of 105mg.

30

Example 4

Suitable pharmaceutical compositions containing the AGENT and an ACE inhibitor in a single dosage form include the following:

5	Capsule	mg
	The AGENT	5.0
	Lisinopril	10.0
	Lactose	42.5
10	Corn starch	20.0
	Microcrystalline cellulose	32.0
	Pregelatinised starch	3.3
	Hydrotalcite	1.1
	Magnesium stearate	1.1

15

Example 5

A patient requiring treatment for diabetic neuropathy is treated with the AGENT (10 mg) and lisinopril (10 mg). Lisinopril is administered twice daily and the AGENT is administered once daily.

20

Example 6

Male Sprague-Dawley rats, 19 weeks old at the start of the study, were divided into non-diabetic animals (normal control group) and animals rendered diabetic by intraperitoneal administration of streptozotocin, (40 - 45 mg/kg, freshly dissolved in sterile saline). Diabetes was verified 24 hours later by estimating hyperglycaemia and glucosuria (Visidex II and Diastix; Ames, Slough, UK). Diabetic rats were tested weekly and weighed daily. Animals were rejected if the plasma glucose concentration was < 20 mM or if body weight consistently increased over 3 days. Samples were taken from the tail vein or carotid artery after final experiments for plasma glucose determination (GOD-Perid method; Boehringer

Mannheim, Mannheim, Germany). After 6 weeks of untreated diabetes, groups of rats were treated for a further 2 weeks with the AGENT, dissolved in the drinking water.

At the end of the treatment period, rats were anaesthetised with thiobutabarbitalone by
5 intraperitoneal injection (50 - 100 mg/kg). The trachea was cannulated for artificial
ventilation and a carotid cannula was used to monitor mean systemic blood pressure.

Motor nerve conduction velocity was measured (as previously described by Cameron et al,
Diabetologia, 1993, Vol. 36, pages 299-304) between sciatic notch and knee in the nerve
10 branch to tibialis anterior muscle, which is representative of the whole sciatic nerve in terms
of susceptibility to diabetes and treatment effects.

Sensory conduction velocity in saphenous nerve was measured between the groin and ankle
(as previously described by Cameron et al. Quarterly Journal of Experimental Physiology,
15 1989, vol. 74, pages 917-926).

Sciatic blood flow was measured by hydrogen clearance microelectrode polarography (as
described by Cameron et al., Diabetologia, 1994, vol.37, pages 651-663). The nerve was
exposed between the sciatic notch and the knee and the skin around the incision was sutured
20 to a metal ring to form a pool that was filled with paraffin oil that was maintained at 35-37°C
by radiant heat. A glass-insulated platinum micro-electrode was inserted into the middle
portion of the sciatic nerve and polarised at 250mV with respect to a subcutaneous reference
microelectrode. 10%Hydrogen was added to the inspired gas, the proportions of nitrogen and
oxygen being adjusted to 70% and 20% respectively. When the hydrogen current recorded by
25 the electrode had stabilised, indicating equilibrium with arterial blood, the hydrogen supply
was shut off and nitrogen supply was increased appropriately. The hydrogen clearance curve
was recorded until a baseline, defined as no systematic decline in electrode current over 5
minutes. To estimate blood flow, clearance curves were digitised and exponential curves
were fitted to the data by computer using non-linear regression. The best fitting exponent gave
30 a measure of nerve blood flow.

Data

All data expressed as group mean \pm SEM (number of rats used in brackets)

5 Sciatic Nerve Motor Conduction Velocity**Control Values**

Non-diabetical control	64.04 \pm 0.46 (10)
8 week diabetic + vehicle	50.35 \pm 0.93 (6)

10

Atorvastatin

9Diabetic + 2 weeks of dosing at 20mg/kg	61.53 \pm 0.76 (6)
Diabetic + 2 weeks of dosing at 50mg/kg	63.59 \pm 0.69 (6)

15 The AGENT

Diabetic + 2 weeks of dosing at 20mg/kg	63.34 \pm 0.61 (8)
---	----------------------

Dose response determination 5 groups of 8 rats - dose ranged from 0.3-20mg/kg -
ED₅₀ = 2.3mg/kg

20 Saphenous Nerve Sensory Conduction Velocity**Control Values**

Non-diabetic control	61.09 m/s \pm 0.67 (10)
8 week diabetic + vehicle	52.77 m/s \pm 0.79 (6)

25

Atorvastatin

Diabetic + 2 weeks of dosing at 20mg/kg	59.77 m/s \pm 0.93 (6)
Diabetic + 2 weeks of dosing at 50mg/kg	60.72 m/s \pm 0.94 (6)

30 The AGENT

Diabetic + 2 weeks of dosing at 20mg/kg	60.57 m/s \pm 0.83 (8)
---	--------------------------

- 15 -

Dose response determination 5 groups of 8 rats - dose ranged from 0.3-20mg/kg -
 $ED_{50} = 0.9\text{mg/kg}$

Sciatic Nerve Blood Flow

5

Control Values

Non-diabetic control	17.89 ml/min/100g (of nerve tissue) \pm 0.65 (10)
8 week diabetic + vehicle	8.82 ml/min/100g \pm 0.56 (10)

10


Atorvastatin

Diabetic + 2 weeks of dosing at 50mg/kg	16.96 \pm 1.39 ml/min/100g (6)
---	----------------------------------

The AGENT

15 Diabetic + 2 weeks of dosing at 20mg/kg	16.19 \pm 0.51 ml/min/100g (8)
--	----------------------------------


Figure 1.




20

The AGENT

- 16 -




Atorvastatin




Fluvastatin

5




Lovastatin


- 17 -



Simvastatin



Pravastatin



Cerivastatin

Claims

1. A method for treating neuropathy in patients suffering from diabetes comprising administering to the patient a statin drug.
- 5 2. A method for improving nerve conduction velocity or nerve blood flow in a patient suffering diabetic neuropathy comprising administering to the patient a statin drug.
3. Use of a statin drug in the preparation of a medicament for use in the treatment of
10 diabetic neuropathy.
4. Use of a statin drug in the preparation of a medicament for use in the improvement of nerve conduction velocity or nerve blood flow in a patient having diabetic neuropathy.
- 15 5. A method as claimed in either claim 1 or claim 2 wherein the statin drug is selected from pravastatin, simvastatin, cerivastatin, fluvastatin, atorvastatin and (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof.
- 20 6. Use as claimed in either claim 3 or claim 4 wherein the statin drug is selected from pravastatin, simvastatin, cerivastatin, fluvastatin, atorvastatin and (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof.
- 25 7. A method as claimed in claim 1, 2 or 5 wherein the statin drug is used in combination with at least one other drug used for treating diabetes or the complications of diabetes.
8. A method as claimed in claim 7 wherein the drug used for treating diabetes or the complications of diabetes is selected from insulin, troglitazone, rosiglitazone, pioglitazone,
30 MCC-555, (S)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl]propanoic acid and 3-{4-[2-(4-*tert*-butoxycarbonylaminophenyl)ethoxy]phenyl}-(S)-2-ethoxy propanoic

- 19 -

acid, glimepiride, glibenclamide, gliclazide, glipizide, gliquidone and tolazamide, metformin, acarbose and repaglinide.

9. Use as claimed in claim 3, 4 or 6 wherein the statin drug is used in combination with
5, at least one other drug used for treating diabetes or the complications of diabetes.

10. Use as claimed in claim 9 wherein the drug used for treating diabetes or the complications of diabetes is selected from insulin, troglitazone, rosiglitazone, pioglitazone, MCC-555, (S)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl]propanoic
10 acid and 3-[4-[2-(4-*tert*-butoxycarbonylaminophenyl)ethoxy]phenyl]-(S)-2-ethoxy propanoic acid, glimepiride, glibenclamide, gliclazide, glipizide, gliquidone and tolazamide, metformin, acarbose and repaglinide.

11. A method as claimed in claim 2 or 5 wherein the statin drug is used in combination
15 with a second drug which is also useful in improving nerve conduction velocity in a patient suffering diabetic neuropathy.

12. A method as claimed in claim 11 wherein the second drug is selected from an aldose reductase inhibitor, an ACE inhibitors and an AII antagonist.

20

13. A method as claimed in claim 12 wherein the second drug is selected from epalrestat, tolrestat, ponolrestat, zopolrestat, AD-5467, SNK-860, ADN-138, AS-3201, zenarestat, sorbinil, methosorbinil, imirestat and minalrestat (WAY-121509), benazepril, benazeprilat, captopril, delapril, fentiapril, fosinopril, imidopril, libenzapril, moexipril, pentopril,
25 perindopril, pivopril, quinapril, quinaprilat, ramipril, spirapril, spiraprilat, trandolapril, zofenopril, ceronapril, enalapril, indolapril, lisinopril, alacepril, cilazapril, losartan, irbesartan, valsartan and candesartan.

14. Use as claimed in either claim 3 or 6 wherein the statin drug is used in combination
30 with a second drug which is also useful in improving nerve conduction velocity in a patient suffering diabetic neuropathy.

15. A method as claimed in claim 14 wherein the second drug is selected from an aldose reductase inhibitor, an ACE inhibitors and an AII antagonist.

5 16. A method as claimed in claim 15 wherein the second drug is selected from epalrestat, tolrestat, ponolrestat, zopolrestat, AD-5467, SNK-860, ADN-138, AS-3201, zenarestat, sorbinil, methosorbinil, imirestat and minalrestat (WAY-121509), benazepril, benazeprilat, captopril, delapril, fentiapril, fosinopril, imidopril, libenzapril, moexipril, pentopril, perindopril, pivopril, quinapril, quinaprilat, ramipril, spirapril, spiraprilat, trandolapril,
10 zofenopril, ceronapril, enalapril, indolapril, lisinopril, alacepril, cilazapril, losartan, irbesartan, valsartan and candesartan.

17. A pharmaceutical combination comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid or a
15 pharmaceutically acceptable salt thereof and lisinopril.

18. A pharmaceutical combination comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof and candesartan.

20

19. A pharmaceutical combination comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof, or atorvastatin, and (S)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl]propanoic acid or 3-{4-[2-(4-*tert*-
25 butoxycarbonylaminophenyl)ethoxy]phenyl}-(S)-2-ethoxy propanoic acid

20. A pharmaceutical composition comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof, lisinopril and a pharmaceutically acceptable diluent
30 or carrier.

21. A pharmaceutical composition comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof, or atorvastatin, (S)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl]propanoic acid, or 3-{4-[2-(4-*tert*-butoxycarbonylaminophenyl)ethoxy]phenyl}-(S)-2-ethoxy propanoic acid, and a pharmaceutically acceptable carrier or diluent.

INTERNATIONAL SEARCH REPORT

Internat'l Application No

PCT/GB 00/00280

A. CLASSIFICATION OF SUBJECT MATTER		
IPC 7	A61K31/505	A61K31/40
	A61K31/415	A61P43/00
A61K31/365 A61K31/22 A61K31/44		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
IPC 7 A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 521 471 A (SHIONOGI SEIYAKU KABUSHIKI KAISHA) 7 January 1993 (1993-01-07) cited in the application examples 1,7 claims 1-9	21
X	US 5 130 333 A (E.R.SQUIBB & SONS, INC.) 14 July 1992 (1992-07-14) abstract column 4, line 27 -column 13, line 15 claims 1,2	1-21
X	EP 0 482 498 A (E.R.SQUIBB & SONS, INC.) 29 April 1992 (1992-04-29) the whole document page 2, line 10 - line 12	1-21
<input type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report
22 May 2000		29/05/2000
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3018		Authorized officer Economou, D

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/GB 00/00280

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0521471 A	07-01-1993	CA 2072945 A	02-01-1993
		HU 61531 A	28-01-1993
		JP 2648897 B	03-09-1997
		JP 5178841 A	20-07-1993
		KR 9605951 B	06-05-1996
		US 5260440 A	09-11-1993
US 5130333 A	14-07-1992	US 5190970 A	02-03-1993
EP 0482498 A	29-04-1992	CA 2052014 A	20-04-1992
		JP 4282324 A	07-10-1992